Provista Tacks On $2.5M, Bringing Series A Funding to $7.5M
September 20, 2012
Provista Diagnostics, an oncology-based testing and laboratory services provider, has added $2.5 million of Series A financing to bring its total Series A round up to $7.5 million. The first $5 million of Series A stock was sold in February and March to investors including Golden Seeds. The company's near-term development and commercialization efforts are currently focused on breast and ovarian cancer.